Up to two-thirds of menstruating women experience abnormal uterine bleeding (AUB) when
treated with oral anticoagulants. However, the true prevalence of AUB for specific agents …

Background Antithrombotic therapies are associated with an increased bleeding risk.
Abnormal uterine bleeding data have been reported in clinical trials of patients with venous …

Introduction There have been reports of clinically relevant uterine bleeding events among
women of reproductive age exposed to rivaroxaban. Objective The aim of this study was to …

Background Although heavy menstrual bleeding (HMB) is a known complication of
anticoagulant therapy, rates of HMB in users of the direct oral anticoagulants (OACs) …

Essentials• Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than
vitamin‐K antagonists (VKA).• We analyzed data of AUB in women, evaluating dabigatran …

Introduction Rivaroxaban is a convenient oral anticoagulant for patients with venous
thromboembolism (VTE). The impact of rivaroxaban and vitamin K antagonists (VKAs) on …

Background Observational data and results from post-hoc analyses in clinical trials suggest
that direct oral factor Xa inhibitors might increase menstrual bleeding intensity in women of …

Abnormal vaginal bleeding can complicate direct oral anticoagulant (DOAC) treatment. We
aimed to investigate the characteristics of abnormal vaginal bleeding in patients with venous …

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of
the potential for fetal complications. It is unknown whether the use of hormonal therapy …

Anticoagulants increase the risk of heavy menstrual bleeding (HMB). We sought to
investigate the incidence, predictors and management of HMB in women on rivaroxaban …